Name: Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: Economic impact of Neovascular age-related macular degeneration on families
Published: 2026-09-28T12:24:10-04:00

Product information and disease description Place of product in therapy Disease description Burden of Neovascular age-related macular degeneration

Economic impact of Neovascular age-related macular degeneration on families

4 evidence topics · 2 sources

Lost work productivity and wages

“Mean wages lost due to impaired work productivity ranged from $1,395 to $55,180.” (opens the source at this quote in a new tab)
“Mean wages lost due to unemployment ranged from $22,314 USD to $58,886 USD a year.” (opens the source at this quote in a new tab)

Unemployment associated with AMD-related vision loss

“The mean unemployment rate attributed to AMD ranged from 5.50% to 77.00%.” (opens the source at this quote in a new tab)

Caregiver work absence and added household expense

“22% requiring a caregiver to take time off from work for transportation.” (opens the source at this quote in a new tab)
“The financial burden of AMD is further exacerbated by additional expenses such as transportation costs, costs for caregivers, and healthcare costs.” (opens the source at this quote in a new tab)

Caregiver time burden per treatment visit

“Approximately half of the patients required caregiver support every visit (37.7%) or occasionally (14.6%)” (opens the source at this quote in a new tab)